Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myelodysplastic SyndromesChronic Myelomonocytic Leukemia-2Secondary Acute Myeloid Leukemia
Interventions
DRUG

unrelated umbilical cord blood

"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."

Trial Locations (1)

210000

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER